INTRODUCTION
Psoriasis is an inflammatory disorder independently associated with heart disease, diabetes, hypertension (HTN), hyperlipidemia (HLD), depression, anxiety, metabolic syndrome, chronic kidney disease, and malignancy.1 There are limited data on the effects of systemic psoriasis treatments on the development of these associated conditions. Conventional psoriasis therapies include methotrexate, cyclosporine, and acitretin; newer biologic treatments include TNF-inhibitors, IL-17 inhibitors, IL-23 inhibitors, and IL-12/23 inhibitors. This study compares patients treated with biologic therapies to conventional therapies with regards to psoriasisassociated comorbidities.
We created a retrospective cohort analysis using the Mount Sinai Data Warehouse, Cohort Query Tool. This de-identified database collects inpatient and outpatient clinical, operational, and financial data from the Mount Sinai Hospital system. We recorded the overlap of patients with a diagnosis code of psoriasis, a diagnosis code of a comorbidity of interest, and a prescription for the medications of interest from January 2002-December 2020.
We created a retrospective cohort analysis using the Mount Sinai Data Warehouse, Cohort Query Tool. This de-identified database collects inpatient and outpatient clinical, operational, and financial data from the Mount Sinai Hospital system. We recorded the overlap of patients with a diagnosis code of psoriasis, a diagnosis code of a comorbidity of interest, and a prescription for the medications of interest from January 2002-December 2020.
Our results (Table 1) demonstrate that there were lower rates of diabetes, angina/myocardial infarction (MI), HTN, and HLD in patients prescribed biologics in comparison with all patients with psoriasis and to patients on conventional therapies. IL-23 inhibitors showed a substantially decreased rate of both depression and anxiety in comparison to all psoriasis patients and conventional therapy. Other biologics showed decreased rates of depression and anxiety in comparison to conventional therapy but were variable in comparison to overall psoriasis.
These results indicate that biologic therapies are correlated with reduced risk of several psoriasis-associated comorbidities.
